Former Indonesian Health Minister Terawan Agus Putranto stated that the Nusantara vaccine for SARS-CoV-2, which produces COVID-19, did not require a third dose.
“What is clear from the one-year review is that the Nusantara vaccine’s ability to defend against COVID-19 in clinical trials one and two is still high,” Terawan said during a Public Hearing Meeting with Commission IX of the Indonesian House of Representatives on Monday (20/6/2022) in Jakarta.
While waiting for Ministry of Health distribution approvals, the Nusantara Vaccine team intends to conduct phase three clinical studies.
He explained, “The medical device distribution authority allows all regions to develop the Nusantara immunization.”
Nusantara Vaccine’s phase three clinical trial was scheduled to include 1,800 people.
“According to the rules, there are 1,800 (subjects), and we’re prepared.” He continued, “This new platform necessitates a new perspective.”
The Nusantara Vaccine is made up of dendritic cells. The toughest Antigen Presenting Cells (APCs) in human are dendritic cells.
“We used dendritic cells to make a COVID-19 vaccine,” he explained.
The vaccine is autologous, individual, contains no harmful components, and is appropriate for people who have low immunity, such as those who have diabetes, chronic kidney disease, autoimmune disease, and others.